Fate Therapeutics Inc · Brief

Next report

12 days

Nov 12 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 8≥ implied

Nov 12 '24±13.6%▼−8.82%×0.65

Mar 5 '25±46.8%▲+14.90%×0.32

May 13 '25±12.1%▼−4.00%×0.33

Aug 12 '25±97.6%▲+20.69%×0.21

Q3 FY25±14.5%▼−4.59%×0.32

Q1 FY26±21.3%▲+5.41%×0.25

May 13 '26±57.5%▼−5.11%×0.09

Q2 FY26±20.5%▼−7.35%×0.36

quarterimplied−100%0+100%realized×

Q2 FY26±20.5%▼−7.35%×0.36

May '26±57.5%▼−5.11%×0.09

Q1 FY26±21.3%▲+5.41%×0.25

Q3 FY25±14.5%▼−4.59%×0.32

Aug '25±97.6%▲+20.69%×0.21

May '25±12.1%▼−4.00%×0.33

2 older reports

Mar '25±46.8%▲+14.90%×0.32

Nov '24±13.6%▼−8.82%×0.65

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 12 report · est.

Bull2

8disclosed supplier and customer ties in SEC filingsSEC filings

155managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

8 of 22of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

17managers whose positions together make up four fifths of the reported value13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

FATE report session

No linked exposure.

Oct 29impliedImplied move: ±43.1% into Nov 12 earnings (Oct 29 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.